RESEARCH
Review examines clinical utility of ctDNA for molecular residual disease detection in colorectal cancerWhile ctDNA detection after curative-intent treatment is a strong prognostic biomarker, randomized trials show mixed results: ctDNA-informed management reduced adjuvant chemotherapy in stage II colon cancer but did not establish non-inferiority in stage III, and cytotoxic escalation for ctDNA-positive MRD has not improved recurrence-free survival. (Lancet Regional Health Western Pacific)